Please login to the form below

Not currently logged in
Email:
Password:

Shire deal with Baxalta predicted this week

Takeover talks reported to be at an advanced stage

ShireShire's negotiations with Baxalta over a takeover have reached an advanced stage and a deal could be announced this week, according to media reports.

If the deal is consummated, it would start 2016 on much the same footing as 2015 and 2014, two years which heralded the return of large-scale M&A to the pharma industry.

Bloomberg says the companies are in the final stages of thrashing out a $32bn deal in cash and stock - excluding debt - that will value Baxalta at somewhere between $46.50 and $48.00 per share. 

Ireland-domiciled Shire has been pursuing Baxter spin-out Baxalta since last summer, saying it wants to create a global biotech company focusing on rare diseases with annual sales of $20bn by 2020, although the latter publicly rejected the unsolicited $45.23 offer as undervaluing its business.

At the time, Baxalta said Shire's approach was a 'lowball valuation' and opportunistic - given that it had only just separated from former parent Baxter its share price had not settled down. It also said its haemophilia business was growing faster than predicted so warranted a much higher valuation than laid out in Shire's proposal.

Pro forma sales for Baxalta are expected to be around $5.9bn in 2015 - roughly 4% down on the prior year - but the company is forecasting 6-8% annual growth year between 2016 and 2020 thanks to the contribution of new drugs that will add around $2.5bn in revenues.

Shire's initial all-stock offer has reportedly been sweetened with a cash element in a bid to win over Baxalta's reluctant shareholders. It has previously said that a merged company would be able to launch up to 30 new drugs over five years.

Shire has been on the acquisition trail since a $55bn takeover by AbbVie was abandoned in 2014, agreeing a $65bn deal to buy Dyax in November 2015 - adding experimental hereditary angioedema (HAE) therapy DX-2930 - and a $5.2bn purchase of NPS Pharma which gave it control of Natpara (recombinant parathyroid hormone) for hypoparathyroidism.

Article by
Phil Taylor

4th January 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. We are an award-winning agency with over 30...

Latest intelligence

The Young Dementia Network - much more than a logo
Welcome to the second and final part of my two-part blog....
Patient-centred care innovation in dementia: a conversation with Neil Maiden
Content Marketing Manager Liz Inskip interviews Neil Maiden of City, University of London, about his work developing mobile technology solutions for residential dementia care, and what the challenges facing innovators...
Issue 4: SPOTLIGHT ON… Medical Communications in 2017
Make 2017 the year to be heard!...

Infographics